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Abstract
Growth factors, such as myostatin (Mstn), play an important role in regulating post-natal myogenesis. In fact, loss of Mstn
has been shown to result in increased post-natal muscle growth through enhanced satellite cell functionality; while elevated
levels of Mstn result in dramatic skeletal muscle wasting through a mechanism involving reduced protein synthesis and
increased ubiquitin-mediated protein degradation. Here we show that miR-27a/b plays an important role in feed back auto-
regulation of Mstn and thus regulation of post-natal myogenesis. Sequence analysis of Mstn 39 UTR showed a single highly
conserved miR-27a/b binding site and increased expression of miR-27a/b was correlated with decreased expression of Mstn
and vice versa both in vitro and in mice in vivo. Moreover, we also show that Mstn gene expression was regulated by miR-
27a/b. Treatment with miR-27a/b-specific AntagomiRs resulted in increased Mstn expression, reduced myoblast
proliferation, impaired satellite cell activation and induction of skeletal muscle atrophy that was rescued upon either
blockade of, or complete absence of, Mstn. Consistent with this, miR-27a over expression resulted in reduced Mstn
expression, skeletal muscle hypertrophy and an increase in the number of activated satellite cells, all features consistent
with impaired Mstn function. Loss of Smad3 was associated with increased levels of Mstn, concomitant with decreased miR-
27a/b expression, which is consistent with impaired satellite cell function and muscular atrophy previously reported in
Smad3-null mice. Interestingly, treatment with Mstn resulted in increased miR-27a/b expression, which was shown to be
dependent on the activity of Smad3. These data highlight a novel auto-regulatory mechanism in which Mstn, via Smad3
signaling, regulates miR-27a/b and in turn its own expression. In support, Mstn-mediated inhibition of Mstn 39 UTR reporter
activity was reversed upon miR-27a/b-specific AntagomiR transfection. Therefore, miR-27a/b, through negatively regulating
Mstn, plays a role in promoting satellite cell activation, myoblast proliferation and preventing muscle wasting.
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Introduction
Myostatin (Mstn) is a secreted growth factor that belongs to the
TGF-b super-family. Mstn is produced predominantly in skeletal
muscle with lower levels of expression observed in white adipose
tissue [1], heart [2] and mammary gland [3]. Analysis has revealed
that Mstn is a profound negative regulator of muscle growth; while
inactivation or mutation of the Mstn gene leads to increased
skeletal muscle mass [1,4], enhanced myoblast proliferation [5],
differentiation [6] and improved skeletal muscle regeneration [7],
increased levels of Mstn result in severe cachectic-like muscle
wasting [8–11].
The expression of Mstn is initially detected at embryonic day 9.5
in developing somites and continues to be detected postnataly in
adult skeletal muscle fibers [1]. Furthermore, the mRNA
expression of Mstn is developmentally regulated. While relatively
abundant expression of Mstn is observed during fetal development,
following birth the expression of Mstn rapidly decreases and
remains quite low during postnatal development [12]. Previous
work has also demonstrated that in adult skeletal muscle the
expression of Mstn is greater in fast-twitch when compared to
slow-twitch muscles [13,14] and thus is speculated to play a role in
regulating muscle fiber type. Although we know that the
expression of Mstn is regulated during myogenesis the exact
mechanisms through which the abundance of Mstn is regulated
remain to be fully determined. However, work from our lab has
revealed that Mstn is transcriptionally regulated by the transcrip-
tion factor MyoD through E-Box elements contained within the
enhancer region of the Mstn gene [15]. In addition, further work
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has demonstrated that Mstn is able to negatively auto-regulate its
own expression through a Smad7-dependent mechanism [16]. In
eukaryotes, transcriptional regulation is not the only mechanism
through which gene expression is controlled. Most notably, post
transcriptional regulation of mRNA stability and translation
through the action of microRNAs (miRNAs) plays a major role
in regulating mRNA abundance. miRNAs are short single
stranded RNAs that can bind specifically to complementary
sequences found in 39 untranslated regions (UTR) of target
mRNAs, resulting in either repression of translation or degrada-
tion of mRNAs through the RNA-induced silencing complex
(RISC) [17,18]. Previously published work has revealed that Mstn
levels are regulated by miRNAs. Specifically, transgenic over
expression of miR-208a in the heart has been shown to result in
cardiac hypertrophy together with reduced expression of Mstn
[19]. Furthermore, over expression of miR-499 leads to reduced
Mstn 39UTR activity, suggesting that Mstn is a target of miR-499
[20]. In addition, essential amino acids have been shown to
promote muscle hypertrophy by not only suppressing Mstn levels
but by inducing greater expression of miR-499, -208b, -23a, -1,
and -206 [21]. Interestingly, a naturally occurring gain of function
mutation in the 39UTR region of the Texel sheep Mstn gene
creates a miR-206 site causing translational inhibition of Mstn
expression and a double muscling phenotype [22]. More recently,
microRNA-27 (miR-27) has been shown to target and inhibit
Mstn. Work by Allen and Loh revealed that miR-27a/b is able to
reduce Mstn expression and mRNA stability and moreover
indicated miR-27a/b may play a role in the increased expression
of Mstn observed firstly, in Fast-twitch muscle, when compared to
slow-twitch muscle and secondly, in response to Dexamethasone
treatment [23]. Similarly, Huang et al revealed that over
expression of miR-27a through addition of miR-27a mimics
resulted in reduced Mstn mRNA expression and increased
myoblast proliferation [24], consistent with known Mstn function.
Here we now show further evidence to support that Mstn gene
expression is regulated by the miR-27a/b, as such AntagomiRs
against miR-27a/b were able to increase Mstn expression, reduce
myoblast proliferation and induce myotubular atrophy. Impor-
tantly, AntagomiR-27a/b-mediated myotube atrophy was due to
increased Mstn function, as either blockade or complete absence of
Mstn rescued the myotubular atrophy. Furthermore, results
confirm a role for miR-27a/b in regulating muscle fiber type-
specific and tissue-specific expression of Mstn and suggest that
miR-27a/b may play a role in regulating Mstn expression and thus
function during myogenic differentiation. We further show the
utility of miR-27a/b in regulating Mstn expression and activity in
vivo and that in Smad3-null mice there is increased expression of
Mstn, which is due to reduced endogenous miR-27a/b expression
in these mice. Results also reveal for the first time that Mstn up
regulates the expression of miR-27a/b via Smad3, which in turn
targets and represses Mstn, forming the basis of a novel
microRNA-mediated Mstn negative auto-regulatory loop during
myogenesis.
Materials and Methods
Ethics Statement
All experiments involving animals were approved by the
Nanyang Technological University Institutional Animal Care
and Use Committee (NTU-IACUC), Singapore (Approval Num-
ber: ARF SBS/NIE-A 0057). All surgery was performed under
Ketamine/Xylazine anesthesia and all efforts were made to
minimize animal suffering.
Animals
Four-six-week-old C57BL/6J male wild type (WT) mice were
obtained from the National University of Singapore Centre for
Animal Resources, Singapore. Myostatin-null mice (Mstn2/+) were
gifted by Prof. See-Jin Lee (Johns Hopkins University, Baltimore,
MD, USA). All mice were housed in groups at a constant
temperature (20uC) under a 12 h/12 h artificial light/dark cycle
with free access to water. To study the effect of miR-27a blockade
in vivo, 20 nM (25 ml total volume; in sterile nuclease free water) of
each AntagomiR (AntagomiR-27a or AntagomiR Neg) oligonu-
cleotides [25], was injected into the M. tibialis anterior (TA) muscle
of anaesthetized WT mice (n = 3) using a 28-gauge syringe
(Hamilton Co., Reno, NV, USA). The contralateral limb of each
mouse was injected with negative control AntagomiR (AntagomiR
Neg). In vivo transfection of plasmid DNA (pcDNA-miR-27a or
pcDNA-miR-neg) was performed by intramuscular injection of
25 mg (25 ml total volume; in sterile PBS) of each plasmid DNA
into the TA muscle of anaesthetized mice. The contralateral limb
of each mouse was injected with the empty vector (pcDNA-miR-
neg) as a control. Electrical pulses (50 Volts/cm, 5 pulses, 200 ms
intervals) were then applied with two platinum electrodes placed
on either side of the muscle belly, using the ECM 830
Electroporation system (BTX Instrument Division, Harvard
Apparatus, Inc. MA, USA). Eight days post-injection, M. tibialis
anterior (TA) muscles from both sides of the hind-limb were
harvested for histological and molecular analysis. For staining of
skeletal muscle sections, TA muscles were covered with OCT
compound and then frozen in isopentane cooled with liquid
nitrogen. Transverse sections (8 mm) were cut from the mid-belly
of the muscle and mounted on slides for hematoxylin and 1%
eosin (H&E) staining and for detection of MyoD and Pax7 by
immunocytochemistry. Images were captured using the Leica
CTR 6500 microscope equipped with the Leica DFC 420 camera
and Image Pro Plus software (Media Cybernetics, Bethesda, MD).
Muscle fiber size was measured as Cross Sectional Area (CSA)
from 500 myofibers per mouse (n = 3).
C2C12 myoblast cell culture
Mouse C2C12 myoblasts, obtained from American Type
Culture Collection (Manassas, VA, USA), were maintained as
previously described [26]. Assessment of C2C12 myoblast
proliferation was performed as previously described [6,26]. Briefly,
C2C12 myoblasts were seeded at a density of 1000 cells/well in
96-well plates in proliferation medium (DMEM, 10% FBS and 1%
P/S; Invitrogen, Carlsbad, CA, USA). After an overnight
attachment period, myoblasts were transfected with 25 nM each
of AntagomiRs specific for miR-27a (AntagomiR-27a), miR-27b
(AntagomiR-27b) or negative control AntagomiR (AntagomiR
Neg) (Dharmacon Inc, USA) using Lipofectamine 2000 (LF2000;
Invitrogen, USA), as per the manufacturer’s guidelines. Following
a further period of 72 h growth, proliferation was assessed using
the methylene blue photometric end-point assay, as previously
described [27], where absorbance at 655 nm is directly propor-
tional to final cell number. To assess the effect of miR-27a/b
blockade on differentiated myotubes and to study the effect of
Mstn blockade on AntagomiR-27a/b-mediated myotube atrophy,
C2C12 myoblasts were induced to differentiate on Thermanox
coverslips under low-serum conditions (DMEM, 2% Horse Serum)
for 24 h. Following this, 24 h differentiated C2C12 myoblasts
were transfected, using LF2000, with 50 nM each of AntagomiR-
27a, AntagomiR-27b or AntagomiR Neg. Twelve hours following
transfection, cells were then treated with either vehicle (Dialysis
buffer; DB) or with a soluble form of the Activin receptor Type IIB
(sActRIIB) at a final concentration of 3 mg/ml and allowed to
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differentiate for 72 h. The expression and purification of the
sActRIIB Mstn antagonist was performed as previously described
[28]. Differentiated Myotubes were then fixed with ethanol:for-
maldehyde:glacial acetic acid (20:2:1) and stained with H&E.
Images of the cultures were then captured and myotube area
assessed. Mstn-overexpressing CHO cells were kindly gifted by Dr.
Se-Jin Lee, Johns Hopkins University, USA. Mstn-overexpressing
CHO cells were propagated and Mstn protein containing
conditioned medium (CMM) was collected as described previously
[11]. The final concentration of Mstn protein present in all CMM
treatments was 10 ng/ml, as estimated by ELISA (Immundiag-
nostik, Bensheim, Germany). Conditioned medium collected from
control CHO cells (CCM) was used as a control for CMM
treatment experiments. For Mstn treatment, C2C12 myoblasts
were either grown for 16 h or were differentiated for 48 h before
further treatment with either CMM or CCM for 12 h.
Primary myoblast culture
Mouse primary myoblasts were cultured from hind-limb
muscles isolated from WT and Mstn2/2 mice using a modified
method of Partridge TA [29]. Briefly, hind-limb muscles were
excised, minced and then digested in 0.2% collagenase type 1A for
90 min. Fibroblasts were removed by pre-plating the cells on
uncoated plates for 3 h at 37uC 5% CO2. Primary myoblasts were
cultured on 10% Matrigel (BD Biosciences) coated plates and were
maintained in proliferation medium, (DMEM, 20% FBS, 10%
HS, 1% P/S and 1% Chicken Embryo Extract) at 37uC 5% CO2.
Primary myoblasts were induced to differentiate, transfected with
either AntagomiR-27a or AntagomiR Neg and fixed and stained
with H&E, as described above. Images of the cultures were then
captured and myotube area assessed.
Specific Inhibitor of SMAD3 (SIS3) treatment
C2C12 myoblasts were differentiated (as described above) for
48 h followed by a further 24 h in the absence (0.05% DMSO) or
presence of the SMAD3-specific inhibitor SIS3 (10 mM; Sigma-
Aldrich). Cells were then harvested for total RNA isolation and
subsequent quantitative real-time PCR (qPCR) analysis.
Detection of MyoD and Pax7 by immunofluorescence
Muscle sections were fixed in 4% paraformaldehyde for 5 min
and then permeabilized in 0.2% PBS-Tween 20. After this,
sections were blocked in a solution containing 6% mouse IgG
blocking reagent (MOM Immunodetection kit; Vector laborato-
ries, Inc, CA, USA) and 3% bovine serum albumin (BSA) in PBS
for 1 h, followed by 5 min in MOM protein diluent with 1.5%
BSA in PBS, as per the manufacturer’s instruction. Muscle sections
were then stained with mouse monoclonal anti-Pax7 (Develop-
mental Studies Hybridoma Bank; DSHB, Iowa City, IA, USA;
1:1000) primary antibody in 1.5% BSA in PBS overnight at 4uC.
Following incubation with horse biotinylated anti-mouse IgG
(Vector laboratories, Inc., CA, USA; 1:500), rabbit polyclonal
anti-Laminin (Sigma-Aldrich, Singapore; 1:1000) and rabbit
polyclonal anti-MyoD (Santa Cruz, USA; 1:40) for 3 h, the
sections were then washed and stained with Streptavidin
conjugated Alexa Fluor 488 (Invitrogen; 1:1000) and goat anti-
rabbit Alexa Fluor 594 (Invitrogen; 1:1000) for 30 min. Nuclei
were counterstained with 496-diamidino-2-phenylindole (DAPI)
(Invitrogen) before mounting with prolong gold anti-fade mount-
ing medium (Invitrogen). Pax7+ cells and activated myoblasts
(MyoD+) that lie underneath the basal lamina, as detected through
Laminin staining, were counted and expressed as the percentage of
positive nuclei per 100 myofibers. Images were captured using
either the Nikon A1Rsi confocal microscope equipped with
Photometrics CoolSNAP HQ2 camera, or the Leica CTR 6500
microscope equipped with Leica DFC 420 camera and Image Pro
Plus software (Media Cybernetics, Bethesda, MD).
Plasmids
The 39-UTR of murine Mstn (1,448 bp) was PCR amplified
using the following primers 59-AAG CTT GCT TTG CAT TAG
GTT-39, 59-AAG CTT GCC TTT CAA AAA TG-39 and cloned
as a HindIII fragment into the pMIR-REPORTTM miRNA
Expression Luciferase Reporter Vector system (Life Technologies).
The construct was sequence verified and namedMstn 39UTR. The
predicted miR-27a/b binding site within the Mstn 39 UTR was
mutated using a PCR-based mutagenesis approach with combi-
nations of the primers above and the following megaprimer 59-
CCC CTC AAT TTC GAA GTC ACA GGT TCA AGC ACC
ACA GG-39, as per the protocol by Picard et al 1994 [30]. The
mutated Mstn 39 UTR was then cloned as a HindIII fragment into
the pMIR-REPORTTM expression reporter vector, sequence
verified to confirm mutation of the miR-27a/b binding region
and named Mstn 39UTR-mut.
The pcDNA 6.2-GW/6 EmGFP expression vector containing
mature miR-27a (pcDNA-miR-27a) was used for miR-27a over
expression studies. The pcDNA 6.2-GW/6 EmGFP empty vector
(pcDNA-miR-neg) was used as a control.
The miR-27a promoter (miR-27a pro), miR-27b promoter
(miR-27b pro) and the mutant miR-27b promoter reporter
construct (miR-27b pro-mut) used in this study were kindly gifted
by Dr Xiao Yang (State Key Laboratory of Proteomics, Genetic
Laboratory of Development and Diseases, Institute of Biotechnol-
ogy, Beijing, China) and have been described previously [31,32].
Transfections and Luciferase assay
For co-transfection of reporter plasmids and miR-27a over
expressing vectors, C2C12 myoblasts were seeded into 24-well
plates at a density of 15,000 cells/cm2 24 h before transfection.
Proliferating C2C12 myoblasts were co-transfected with 0.1 mg
Mstn 39UTR or Mstn 39UTR-mut reporter plasmids and 0.4 mg
pcDNA-miR-27a or pcDNA-miR-neg, as a negative control.
Transfection was carried out with LF2000 (Invitrogen, USA)
according to the manufacturer’s protocol. For co-transfection of
reporter plasmids and AntagomiRs against miR-27a/b, 50 nM of
AntagomiR-27a, AntagomiR-27b or AntagomiR Neg were co-
transfected with Mstn 39UTR or Mstn 39UTR-mut using LF2000
(Invitrogen, USA) as per the manufacturer’s protocol. After 48 h
of transfections, cells were lysed, and luciferase assays were
performed on protein extracts using the Dual-Luciferase reporter
system (Promega, USA), according to the manufacturer’s recom-
mendations. To assess for miR-27a and miR-27b promoter
reporter activity, miR-27a pro, miR-27b pro and miR-27b pro-
mut constructs were electroporated (GenePulsar MXcell, Bio-rad,
Hercules, CA, USA) into 1 million C2C12 cells and grown to
confluency. The electroporated C2C12 myoblasts were then
replated at a density of 15,000 cells/cm2 in 24 well plates and
treated with (10 mM) or without (0.05% DMSO) SIS3 in the
presence (CMM; 10 ng/ml) or absence (CCM) of Mstn for 24 hrs.
Following transfections, cells were lysed, and luciferase assays were
performed on protein extracts using the Dual-Luciferase reporter
system (Promega, USA), according to the manufacturer’s recom-
mendations. Renilla and firefly luciferase signals were detected
using the GloMax luminometer (Promega, USA). AntagomiRs
(AntagomiR-27a, AntagomiR-27b and AntagomiR Neg) were
synthesized by Dharmacon Inc, USA. Synthetic miR-27b mimic
and non-targeting miRNA negative control mimic were obtained
from Dharmacon. A final concentration of 50 nM each of miR-
MicroRNA-27 and Myostatin Auto-Regulation
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27b mimic and miRNA negative control were transfected into wild
type (WT) and Smad3-null mouse primary myoblasts using LF2000
(Invitrogen) as per the manufacturer’s protocol. Following
transfection primary myoblasts were induced to differentiate
under low-serum conditions (DMEM, 2% Horse Serum) for
72 h and then harvested for total RNA isolation and subsequent
qPCR analysis.
RT-PCR and quantitative real-time PCR (qPCR)
Total RNA was extracted using TRIzol reagent according to
the manufacturer’s protocol (Invitrogen, USA). cDNA was
synthesized from 1 mg of total RNA using the iScript cDNA kit
(Bio-rad, USA) as per the manufacturer’s guidelines. qPCR
analysis of precursor-miR-27a/b (Pre-miR-27a/b) and Mstn
expression was performed using the CFX96 Real-Time System
(Bio-rad). Each qPCR reaction (10 ml) contained 3 ml of diluted
cDNA, 5 ml of 2 X SsoFast Evagreen (Bio-rad) and primers at a
final concentration of 200 nM. All reactions were performed using
the following thermal cycle conditions: 98uC for 3 min followed by
45 cycles of a two step reaction, denaturation at 98uC for 3 sec and
annealing at 60uC for 20 sec, followed by a denaturation curve
from 60uC to 95uC in 5 sec increments of 0.5uC to ensure
amplification specificity. To assess for the expression of mature
miR-27a and miR-27b, cDNA was synthesized from extracted
RNA using the miScript II RT kit (Cat# 218161; Qiagen), as per
the manufacturer’s instructions. qPCR was then conducted using
miR-27a or miR-27b mature miRNA specific miScript forward
primers, referred to as Primer Assays (Cat# MS00001351 and
Cat# MS00001358 respectively; Qiagen), miScript universal
reverse primer (Qiagen) and miScript SYBR Green PCR Kit
(Cat# 218075; Qiagen). The expression of mRNAs and miRNAs
were normalized to GAPDH and U6, respectively. The following
mouse-specific primers were used for qPCR analysis: precursor-
miR-27a/b (pre-miR-27a/b) Forward 59-GCA GGG CTT AGC
TGC TTG-39, Reverse 59-GGC GGA ACT TAG CCA CTG T-
39; Mstn Forward 59-AGT GGA TCT AAA TGA GGG CAG T-
39, Reverse 59-GTT TCC AGG CGC AGC TTA C-39; U6
Forward 59-CTC GCT TCG GCA GCA CA-39 Reverse 59-AAC
GCT TCA CGA ATT TGC GT-39; GAPDH Forward 59-ACA
ACT TTG GCA TTG TGG AA-39, Reverse 59-GAT GCA GGG
ATG ATG TTC TG-39.
Statistical analysis
Statistical analysis was performed using two-tail Student’s-t-test
and ANOVA. Data are expressed as mean 6SEM and p,0.05
were considered significant. Experimental replicates are described
in relevant figure legends.
Results
miR-27a/b targets and represses Mstn through a miR-
27a/b-specific target site in the 39 UTR of the Mstn gene
In agreement with previously published reports [23,24], analysis
with the TargetScan5.1 (http://www.targetscan.org/) algorithm
revealed the presence of a single target site for microRNA-27a/b
(miR-27a/b) in the 39UTR of the murine Mstn gene (Figure 1A).
Importantly, TargetScan analysis revealed an 8 mer seed match,
defined as a perfect match to positions 2–8 of the mature miRNA
followed by an adenine, between the miR-27a and miR-27b seed
sequence and the miR-27a/b binding site in the 39UTR of the
murine Mstn gene (Figure 1A). Furthermore the mstn 39UTR miR-
27a/b target site was found to be flanked by AU-rich sequences,
which act to boost miRNA efficacy [33].
To further study miR-27a/b regulation of Mstn, we cloned the
39 UTR region of the murine Mstn gene into the pMIR-
REPORTTM miRNA Expression Luciferase Reporter Vector
and co-transfected together with a miR-27a over expression vector
(pcDNA-miR-27a). A significant reduction in Mstn 39UTR
reporter luciferase activity was observed in myoblasts co-
transfected with Mstn 39UTR and pcDNA-miR-27a, when
compared with myoblasts co-transfected with Mstn 39UTR and
control (pcDNA-miR-neg) (Figure 1B). To identify if miR-27a/b
target site was responsible for the reduced luciferase activity
observed, the putative miR-27a/b binding site in the Mstn 39UTR
was mutated. When pcDNA-miR-27a was co-transfected together
with the mutant Mstn 39UTR reporter (Mstn 39UTR-mut), no
significant reduction in luciferase activity was observed (Figure 1C).
Furthermore co-transfection of Mstn 39UTR with a miR-27a-
specific AntagomiR (AntagomiR-27a) resulted in significant
increase in Mstn 39UTR reporter luciferase activity, over and
above that observed in control AntagomiR Neg transfected cells
(Figure 1B). The effect of AntagomiR-27a appeared to be specific
to the miR-27a/b site in the Mstn 39UTR site, since addition of
AntagomiR-27a failed to increase luciferase activity in Mstn
39UTR-mut reporter transfected myoblasts (Figure 1C). These
data strongly suggest that miR-27a/b is able to negatively regulate
Mstn mRNA and that the miR-27a/b target site found within the
Mstn 39UTR is critical for miR-27a/b regulation of Mstn.
Correlation between Mstn and miR-27a/b expression in
vivo and in vitro
While high levels of Mstn are detected in skeletal muscle, lower
levels of Mstn are expressed in white adipose tissue, heart and
mammary gland [1–3]. Furthermore, Mstn expression is higher in
fast-twitch muscles, when compared to slow-twitch muscles
[13,14]. To investigate whether or not miR-27a/b plays a role
in regulating tissue-specific Mstn expression, we analyzed precur-
sor-miR-27a/b (pre-miR-27a/b) and Mstn expression profiles in
various tissues. When compared to liver and biceps femoris (BF)
muscle, we noted reduced expression of Mstn and increased
expression of pre-miR-27a/b in the heart (Figure 1D and 1E). On
the other hand in tissues where relatively higher levels ofMstn were
observed, such as liver and BF muscle, lower pre-miR-27a/b
expression was detected (Figure 1D and 1E). Consistent with the
data published by Allen and Loh [23], we also observed a
difference in Mstn and pre-miR-27a/b expression between fast-
twitch and slow-twitch muscles. qPCR analysis revealed signifi-
cantly increased Mstn mRNA expression, concomitant with
reduced pre-miR-27a/b expression in the predominantly fast-
twitch BF muscle, when compared to the slow-twitch soleus (Sol)
muscle (Figure 1D and 1E).
Next we also compared the expression of Mstn and miR-27a/b
during differentiation in C2C12 myoblasts. Subsequent qPCR
revealed that there was relatively higher expression of Mstn at 24 h
differentiation, which sharply declined from 48 h differentiation
onwards in C2C12 myoblasts (Figure 1F). However in contrast, we
observed a gradual increase in miR-27b expression from 24 h
through to 96 h differentiation (Figure 1G). Thus, the expression
of Mstn appears to be inversely associated with miR-27a/b
expression during C2C12 myoblast differentiation.
AntagomiR-mediated blockade of miR-27a/b leads to
enhanced Mstn activity
Mstn, as a negative regulator of skeletal muscle growth, has
been previously demonstrated to inhibit myoblast proliferation
and moreover induce severe myotubular atrophy in vitro [5,8,9].
MicroRNA-27 and Myostatin Auto-Regulation
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Therefore, we next assessed the effect of AntagomiR-27a and
AntagomiR-27b transfection on Mstn function during myogenesis.
As predicted, transfection of AntagomiR-27a or AntagomiR-27b
resulted in reduced expression of miR-27a (Figure S1A) and miR-
27b (Figure S1B) respectively, together with increased Mstn
expression (Figure S1C). Next we assessed C2C12 myoblast
proliferation following treatment with conditioned medium
collected from Control (AntagomiR Neg), AntagomiR-27a or
AntagomiR-27b transfected C2C12 myoblasts. As shown in
Figure 2A, we observed a significant decrease in myoblast
proliferation in C2C12 myoblasts treated with conditioned
medium collected from AtagomiR-27a and AntagomiR-27b
transfected cells, when compared to control (AntagomiR Neg)
transfected cells (Figure 2A).
In addition, transfection of either AntagomiR-27a or Antag-
omiR-27b into differentiating C2C12 myotubes resulted in
noticeable myotubular atrophy when compared to AntagomiR
Neg transfected myotubes (Figure 2B). Subsequent quantification
revealed a significant 24% and 26% decrease in average myotube
area in AntagomiR-27a and AntagomiR-27b transfected myo-
tubes respectively, when compared to AntagomiR Neg transfected
myotubes (Figure 2C). Consistent with blockade of miR-27a/b
and with the development of myotube atrophy a significant
increase in Mstn expression was observed following transfection of
C2C12 myotubes with AntagomiR-27a or AntagomiR-27b
(Figure S1D).
To confirm whether or not the myotube atrophy observed
following AntagomiR-mediated blockade of miR-27a/b was due
to enhanced Mstn function, we next assessed myotube area in
AntagomiR-27a and AntagomiR-27b transfected C2C12 myo-
tubes cultures treated together with soluble Activin type IIB
receptor (sActRIIB) Mstn antagonist. Treatment of AntagomiR-
27a and AntagomiR-27b transfected C2C12 myotubes with
sActRIIB rescued the myotubular atrophy observed in the
AntagomiR only transfected myotubes (Figure 2B). Subsequent
quantification revealed an ,40% and ,30% increase in average
myotube area, which was similar to that observed in AntagomiR
Neg transfected myotubes, in sActRIIB treated AntagomiR-27a
and AntagomiR-27b transfected myotubes respectively, when
compared to respective vehicle control (Dialysis buffer; DB)
treated transfected myotubes (Figure 2C).
In agreement with the results above, AntagomiR-mediated
reduction of miR-27a expression (Figure S1E) did not result in any
appreciable myotube atrophy in Mstn-null mice-derived primary
myotube cultures, when compared to AntagomiR Neg transfected
primary myotubes (Figure 2D & 2E). However, in contrast,
AntagomiR-mediated reduction of miR-27a in primary myotubes
cultures isolated from WT mice (Figure S1F) led to elevated Mstn
expression (Figure S1G) and observable myotubular atrophy
(Figure 2D & 2E), with an ,32% decrease in average myotube
area observed in AntagomiR-27a transfected myotubes, when
compared to AntagomiR Neg transfected myotubes (Figure 2E).
These results confirm that blockade of miR-27a/b results in
myotube atrophy through a mechanism dependent on Mstn.
miR-27a/b regulates myofiber size and SC function
through targeting endogenous Mstn expression in
skeletal muscle
To investigate whether miR-27a/b regulates endogenous Mstn
levels in skeletal muscle, M. tibialis anterior (TA) muscles of WT
mice were intramuscularly injected and in vivo electroporated with
either the pcDNA-miR-27a over expression construct or control
(pcDNA-miR-neg). The expression of Mstn was quantified by
qPCR 8 days post-injection and as shown in Figure 3A
overexpression of miR-27a in vivo resulted in a significant
reduction in Mstn expression in TA muscle. Since Mstn is a
potent negative regulator of skeletal muscle mass and satellite cell
(SC) function [1,4,7,34], we also stained TA muscle serial sections
with H&E (Figure 3B) and quantified myofiber cross sectional area
(CSA), as well as the percentage of Pax7+ and MyoD+ cells in TA
muscle following miR-27a overexpression. An ,30% increase in
average myofiber CSA was observed in miR-27a overexpressing
TA muscle, when compared to the control transfected contralat-
eral TA muscle (Figure 3C). Furthermore we also observed an
,52% increase in the number of very large myofibers
(.2500 mm2) and an ,60% decrease in the number of very small
myofibers (,1500 mm2) upon in vivo overexpression of miR-27a
(Figure 3D), which is quite consistent with the increased myofiber
CSA and loss of Mstn function. Interestingly, detection of Pax7
and MyoD by immunofluorescence (Figure 3E & S1H) revealed a
significant,12% and,7% increase in the pool of Pax7+ cells and
activated myoblasts (MyoD+) respectively in pcDNA-miR-27a
transfected TA muscle, when compared with control-transfected
muscle (Figure 3E & 3F).
To further confirm regulation of endogenousMstn expression by
miR-27a, we also injected either an AntagomiR specific for miR-
27a (AntagomiR-27a) or a non-silencing negative control Antag-
omiR (AntagomiR Neg) into TA muscle of WT mice. The
expression of Mstn was assessed 8 days post-injection and
consistent with reduced miR-27a,Mstn expression was significantly
up regulated, albeit modestly, upon AntagomiR-mediated block-
ade of miR-27a in vivo, when compared to AntagomiR Neg
transfected contralateral TA muscle. (Figure 4A). We further
stained TA muscle serial sections with H&E (Figure 4B) and
although no significant difference was noted in average myofiber
CSA (Figure 4C), we did observe an ,25% increase in the
number of very small myofibers (,1500 mm2) and an ,10%
decrease in the number of very large myofibers (.2500 mm2)
(Figure 4D), which is quite consistent with the elevated Mstn
Figure 1. miR-27a/b targets and represses Mstn expression. (A) In silico analysis, using TargetScan algorithms, showing a 8 mer seed match
(grey box) between murine miR-27a (mmu-miR-27a) and miR-27b (mmu-miR-27b) and the miR-27a/b binding site located within the Mstn 39 UTR
sequence (mmu-Mstn 39UTR). (B) Assessment of pMIR-REPORTTM luciferase activity in C2C12 myoblasts co-transfected with the Mstn 39UTR reporter
construct (Mstn 39UTR) and either control (pcDNA-miR-neg), miR-27a over expression construct (pcDNA-miR-27a), negative control AntagomiR
(AntagomiR Neg) or a miR-27a-specific AntagomiR (AntagomiR-27a) for 48h. (C) Assessment of pMIR-REPORTTM luciferase activity in C2C12 myoblasts
co-transfected with the mutant Mstn 39UTR reporter construct (Mstn 39UTR-mut), where the miR-27a/b binding site has been mutated, and either
control (pcDNA-miR-neg), miR-27a over expression construct (pcDNA-miR-27a), negative control AntagomiR (AntagomiR Neg) or a miR-27a-specific
AntagomiR (AntagomiR-27a) for 48h. For all pMIR-REPORTTM transfections, luciferase activity was normalized to Renilla luciferase and expressed as
fold change relative to control (pcDNA-miR-neg). Bars represent mean values 6 S.E.M (n = 3). p,0.05 (*) and p,0.001(***). qPCR analysis of Mstn
mRNA expression (D) and precursor-miR-27a/b (pre-miR-27a/b) expression (E) in Heart, Liver, M. Biceps femoris muscle (BF) and M. Soleus muscle (Sol.)
collected from 4-week-old wild type (WT) mice. Bars represent fold change (relative to Heart) 6 S.E.M (n = 3) normalized to GAPDH (D) or U6 (E)
expression. p,0.05 (*) and p,0.001(***). qPCR analysis of (F)Mstn and (G) miR-27b expression in C2C12 myoblast cultures differentiated across a time
course (24 h, 48 h, 72 h and 96 h differentiation). Bars represent fold change (relative to 24 h control) 6 S.E.M (n = 3) normalized to either GAPDH (F)
or U6 (G) expression. p,0.001(***).
doi:10.1371/journal.pone.0087687.g001
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expression detected. Furthermore, detection of Pax7 and MyoD
by immunofluorescence (Figure 4E & S1H) revealed a significant
,11% and ,4% decrease in the pool of Pax7+ cells and activated
myoblasts (MyoD+) respectively in AntagomiR-27a transfected TA
muscle, when compared with AntagomiR Neg-transfected muscle
(Figure 4E & 4F).
Increased Mstn expression observed in the absence of
Smad3 is due to reduced miR-27a/b expression
Smad3-null mice display severe muscle atrophy, which has been
attributed to elevated endogenous levels of Mstn detected in
Smad3-null mice [35]. Therefore we next wanted to test whether or
not the increased Mstn levels observed in Smad3-null mice was due
to reduced miR-27a/b expression. Consistent with previously
published data, qPCR analysis revealed a significant increase in
Mstn expression in TA, GAS and QUAD muscles isolated from
Smad3-null mice, when compared to WT controls (Figure 5A).
Importantly, the elevated Mstn expression was associated with a
significant decrease in both mature miR-27a and miR-27b
expression in all muscle tissues isolated from Smad3-null mice, as
compared to WT mice (Figure 5B & 5C). Similarly, C2C12
myotubes treated with Specific Inhibitor of Smad3 (SIS3), a
compound previously shown to specifically inhibit Smad3 function
via suppressing Smad3 phosphorylation [36], displayed signifi-
cantly increased Mstn expression concomitant with reduced pre-
miR-27a/b (Figure 5D & 5E). To confirm that the reduced
expression of miR-27 was responsible for the elevated Mstn
expression detected in Smad3-null mice we next assessed Mstn
expression between WT and Smad3-null mice primary myoblast
cultures following transfection of a miR-27b-specific mimic. As
expected Mstn expression was significantly elevated in Smad3-null
cultures, when compared to WT cultures (Figure 5F). Importantly,
transfection of the miR-27b mimic reduced the expression of Mstn
back to levels comparable to that observed in WT controls
(Figure 5F), suggesting that reduced miR-27a/b expression may be
responsible for the increased levels of Mstn observed in Smad3-null
mice.
Mstn upregulates miR-27a/b expression through a
Smad3-dependent mechanism to negatively auto-
regulate its own expression
The data presented above suggested to us that Smad3 may play
an important role in regulating basal miR-27a/b expression in
muscle. Since Mstn is known to activate Smad3, we further
hypothesized that Mstn may signal to up regulate the expression of
miR-27a/b in muscle. To determine whether Mstn regulates miR-
27a/b expression, C2C12 myoblasts and 48 h differentiated
myotubes were treated with conditioned medium containing
eukaryotic produced CHO-cell secreted Mstn protein (CMM) for
12 h. Pre-miR-27a/b expression was quantified by qPCR and as
can be seen in Figure 6A & 6B, the expression of pre-miR-27a/b
was significantly increased in both C2C12 myoblasts and
myotubes upon treatment with CMM, when compared with cells
treated with conditioned medium collected from control CHO
cells (CCM) (Figure 6A & 6B). These data confirm that Mstn is
able to positively regulate miR-27a/b expression in muscle.
To confirm whether Smad3 is involved in Mstn regulation of
miR-27a/b, C2C12 myoblasts were transfected with either the
miR-27a promoter (miR-27a pro), miR-27b promoter (miR-27b
pro) or a mutant miR-27b promoter reporter construct, where the
smad binding site has been mutated (miR-27b pro-mut) and
subjected to treatment with CMM. Treatment with CMM
resulted in a significant increase in promoter-reporter luciferase
activity in myoblasts transfected with either the miR-27a or miR-
27b promoter constructs (Figure 6C); however, no significant
increase in luciferase activity was observed in C2C12 myoblasts
transfected with the mutated miR-27b promoter construct
following CMM treatment (Figure 6C). Transfected myoblasts
were also subjected to treatment with both CMM and SIS3. As
shown in Figure 6C, addition of SIS3 was able to partially rescue
the increased miR-27a- and miR-27b-promoter-reporter luciferase
activity observed following treatment with CMM alone
(Figure 6C). Therefore these data confirm that Smad3 plays a
critical role in the ability of Mstn to up regulate miR-27a/b
expression.
Next we assessed whether or not the increased miR-27a/b, due
to CMM treatment, would in turn target and repress Mstn
expression. To test this C2C12 myoblasts transfected with the Mstn
39UTR reporter were subjected to treatment with CMM. As
shown in Figure 6D, treatment of Mstn 39UTR reporter
transfected myoblasts with CMM resulted in an ,50% reduction
in Mstn 39UTR reporter activity. The ability of CMM to reduce
Mstn 39UTR reporter activity appeared to be dependent on miR-
27a/b function, as AntagomiR-mediated inhibition of miR-27a/b,
as well as mutation of the miR-27a/b binding site in the Mstn
39UTR, prevented CMM-mediated inhibition of Mstn expression
(Figure 6D & 6E). Taken together these data highlight a novel
negative auto-regulatory mechanism through which Mstn signals
to regulate it’s own expression (Figure 6F).
Discussion
In the present study we have further characterized the role of
miR-27a/b in regulating Mstn expression and activity. Evidence
presented here confirms that Mstn is indeed a target of miR-27a/b
both in vitro and in vivo. Consistent with previous reports [23,24],
we show that over expression of miR-27a results in reduced Mstn
39UTR reporter activity, which is blocked upon mutation of the
miR-27a/b binding site in the Mstn 39 UTR. Furthermore, over
expression of miR-27a in vivo led to decreased Mstn expression
concomitant with myofiber hypertrophy and increased numbers of
Pax7+ cells and activated myoblasts (MyoD+); quite consistent with
the fact that loss of Mstn leads to increased muscle mass and
Figure 2. Inhibition of miR-27a and miR-27b results in increased Mstn activity. (A) Analysis of C2C12 myoblast proliferation in cultures
treated with conditioned medium collected from C2C12 myoblasts transfected with either the negative control AntagomiR (AntagomiR Neg), miR-
27a-specific AntagomiR (AntagomiR-27a) or miR-27b-specific AntagomiR (AntagomiR-27b) for 72 h, as monitored by methylene blue assay. Values
represent mean values 6 S.E.M (n = 3). p,0.001 (***). (B) Representative images of H&E stained AntagomiR Neg, AntagomiR-27a or AntagomiR-27b
transfected C2C12 myoblasts after 48 h differentiation, followed by a further 72 h differentiation in the absence (Dialysis buffer; DB) or presence of
3 mg/ml sActRIIB. Scale bars = 100 mm. (C) Quantification of average myotube area (mm2) in AntagomiR Neg, AntagomiR-27a or AntagomiR-27b
transfected C2C12 myoblasts following 72 h differentiation and treatment without (DB) or with sActRIIB. Average myotube area was calculated from
10 random images per coverslip (n = 3) from three independent experiments. p,0.05 (*), p,0.01 (**) and p,0.001 (***). (D) Representative images of
H&E stained AntagomiR Neg or AntagomiR-27a transfected WT and Mstn-null primary myoblasts following 48 h differentiation. Scale bars = 100 mm.
(E) Quantification of average myotube area (mm2) in AntagomiR Neg or AntagomiR-27a transfected WT and Mstn-null primary myoblasts following
72 h differentiation. Average myotube area was calculated from 10 random images per coverslip (n = 3). p,0.001 (***).
doi:10.1371/journal.pone.0087687.g002
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enhanced satellite cell number, activation and self-renewal
[1,4,34]. Previously published work has revealed that hypertrophy
of skeletal muscle may occur independent of satellite cell function
[37]. Consistent with this, hypertrophy of skeletal muscle induced
upon blockade of Mstn, was also shown to occur in the absence of
satellite cells [38,39]. Nevertheless, as satellite cells play a critical
Figure 3. Over expression of miR-27a targets and represses endogenous Mstn expression and function in vivo. (A) qPCR analysis of
Mstn mRNA expression in TA muscle isolated from WT mice (n = 3) 8 days post intramuscular injection and in vivo transfection of either control
(pcDNA-miR-neg) or miR-27a (pcDNA-miR-27a) over expression constructs. p,0.01 (**). (B) Representative images of H&E stained pcDNA-miR-neg
and pcDNA-miR-27a in vivo transfected TA muscle cross sections from WT mice. Scale bars = 100 mm. (C) Graph showing average myofiber cross
sectional area (CSA; mm2) in pcDNA-miR-neg and pcDNA-miR-27a in vivo transfected TA muscle from WT mice. Average myofiber area was calculated
from 10 random images per coverslip (n = 3). p,0.001 (***). (D) Frequency distribution of myofiber area (mm2) in pcDNA-miR-neg and pcDNA-miR-27a
in vivo transfected TA muscle from WT mice as calculated from 10 random images per coverslip (n = 3). (E) Left: Representative merged
immunofluorescence image showing a Pax7+ cell (Green; white arrowhead) in a pcDNA-miR-27a in vivo transfected TA muscle cross section from WT
mice. Sections were also stained for Laminin (Red) and nuclei were counterstained with DAPI (Blue). Scale bar = 10 mm. Right: Graph showing the
number of Pax7+ cells in pcDNA-miR-neg and pcDNA-miR-27a in vivo transfected TA muscle from WT mice. Bars represent mean number 6 S.E.M of
Pax7+ cells, per 100 myofibers, from 3 sections each collected from pcDNA-miR-neg and pcDNA-miR-27a transfected WT mice (n = 3). p,0.01 (**). (F)
Graph showing the number of MyoD+ cells in pcDNA-miR-neg and pcDNA-miR-27a in vivo transfected TA muscle from WT mice. Bars represent mean
number 6 S.E.M of MyoD+ cells, per 100 myofibers, from 3 sections each collected from pcDNA-miR-neg and pcDNA-miR-27a transfected WT mice
(n = 3). p,0.01 (**).
doi:10.1371/journal.pone.0087687.g003
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role during skeletal muscle regeneration [37] and that loss of Mstn
leads to enhanced satellite cell activation, self-renewal and
accelerated skeletal muscle regeneration [7,34] we strongly believe
that the increased numbers of Pax7+ and MyoD+ cells observed
following over expression of miR-27a is due to loss of Mstn.
Recent work from Crist et al has shown that miR-27 is able to
down regulate Pax3 protein levels, without affecting the levels of
Pax7 [40]. However, we now show that over expression of miR-27
Figure 4. AntagomiR-mediated inhibition of miR-27a enhances endogenous Mstn expression and function in vivo. (A) qPCR analysis of
Mstn mRNA expression in TA muscle isolated from WT mice (n = 3) 8 days post intramuscular injection of either AntagomiR Neg or AntagomiR-27a.
p,0.05 (*). (B) Representative images of H&E stained AntagomiR Neg and AntagomiR-27a injected TA muscle from WT mice. Scale bars = 100 mm. (C)
Graph showing average myofiber CSA (mm2) in AntagomiR Neg and AntagomiR-27a injected TA muscle from WT mice. Average myofiber area was
calculated from 10 random images per coverslip (n = 3). (D) Frequency distribution of myofiber area (mm2) in AntagomiR Neg and AntagomiR-27a
injected TA muscle from WT mice as calculated from 10 random images per coverslip (n = 3). (E) Left: Representative merged immunofluorescence
image showing a Pax7+ cell (Green; white arrowhead) in an AntagomiR Neg injected TA muscle cross section from WT mice. Sections were also
stained for Laminin (Red) and nuclei were counterstained with DAPI (Blue). Scale bar = 10 mm. Right: Graph showing the number of Pax7+ cells in
AntagomiR Neg and AntagomiR-27a injected TA muscle from WT mice. Bars represent mean number6 S.E.M of Pax7+ cells, per 100 myofibers, from 3
sections each collected from AntagomiR Neg and AntagomiR-27a injected WT mice (n = 3). p,0.01 (**). (F) Graph showing the number of MyoD+ cells
in AntagomiR Neg and AntagomiR-27a injected TA muscle from WT mice. Bars represent mean number 6 S.E.M of MyoD+ cells, per 100 myofibers,
from 3 sections each collected from AntagomiR Neg and AntagomiR-27a injected WT mice (n = 3). p,0.001 (***).
doi:10.1371/journal.pone.0087687.g004
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in vivo leads to increased numbers of Pax7+ cells. It is important to
highlight that previously published work from our lab revealed
that Mstn is a potent negative regulator of Pax7 expression during
myogenesis. [26]. Therefore, the increase in Pax7+ cells observed
in response to over expression of miR-27 is most likely due to miR-
27-mediated inhibition of Mstn as opposed to direct regulation of
Pax7 by miR-27. In addition to over expression studies, we now
show that blockade of miR-27a, through addition of an
AntagomiR specific for miR-27a, results in enhanced Mstn
39UTR reporter activity. AntagomiR-mediated blockade of miR-
27a and miR-27b not only up regulated Mstn expression but also
significantly reduced C2C12 myoblast proliferation. These data
are consistent with previously published reports demonstrating
that excess Mstn inhibits myoblast proliferation [5] and with a
recent report, which shows that addition of miR-27a mimics
results in decreased Mstn mRNA concomitant with an increase in
the number of proliferating C2C12 myoblasts [24]. In addition to
controlling myoblast growth excess Mstn has been shown to
promote skeletal muscle wasting in vitro and in vivo [10,11]. In
agreement with this, we observed significantly increased expres-
sion of Mstn together with pronounced myotubular atrophy upon
AntagomiR-mediated inhibition of miR-27a and miR-27b. This
effect appeared to be dependent on increased Mstn as sActRIIB-
mediated blockade of Mstn rescued the atrophy phenotype and
moreover primary myotube cultures isolated from Mstn-null mice
were resistant to AntagomiR-induced myotube atrophy. It is
important to mention that we noted differences in the effects of
AntagomiR-27a and AntagomiR-27b on Mstn expression between
proliferating C2C12 myoblasts and differentiated C2C12 myotube
cultures (compare Figure S1C to Figure S1D). Although we do
observe a significant increase in Mstn expression in both C2C12
myoblasts and myotubes transfected with either AntagomiR-27a
or AntagomiR-27b the increase in Mstn was more significant in
AntagomiR transfected myotube cultures, when compared to
proliferating myoblasts. At this stage we do not know why there
are differences in AntagomiR-27a- and AntagomiR-27b-mediated
Figure 5. Increased Mstn expression in Smad3-null mice is due to reduced miR-27a/b expression. qPCR analysis of (A) Mstn, (B) miR-27a
and (C) miR-27b expression in M. Tibialis anteriormuscle (TA), M. Gastrocnemius muscle (GAS) and M. Quadriceps muscle (QUAD) isolated from WT and
Smad3-null mice. Bars represent fold change (relative to respective WT control) 6 S.E.M (n = 3) normalized to either GAPDH (A) or U6 (B & C)
expression. p,0.001 (***). (D) qPCR analysis of Mstn expression in 48 h differentiated C2C12 myotubes treated without (0.05% DMSO) or with SIS3
(10 mM) for 24 h. p,0.001 (***). (E) qPCR analysis of pre-miR-27a/b expression in 48 h differentiated C2C12 myotubes treated without (0.05% DMSO)
or with SIS3 (10 mM) for 24 h. p,0.001 (***). (F) qPCR analysis of Mstn in 72 h differentiated primary myoblast cultures isolated from WT and Smad3-
null mice that were transfected with either non targeting miRNA negative control (miRNA neg control) or miR-27b-specific mimic (miR-27b mimic).
Bars represent fold change (relative to WT miRNA Neg control transfected myoblasts) 6 S.E.M (n = 3) normalized to GAPDH expression. p,0.01 (**)
and p,0.001 (***).
doi:10.1371/journal.pone.0087687.g005
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regulation of Mstn between myoblasts and myotubes, however we
speculate that the AntagomiR effect might be more persistent in
myotube cultures when compared to proliferating myoblasts.
Blockade of miR-27a in vivo also resulted in significantly increased
Mstn expression, which was associated with decreased myofiber
CSA. Unlike the dramatic phenotype observed in vitro, Antag-
omiR-mediated blockade of miR-27a only resulted in minor
muscle atrophy. However, it is important to mention that we only
observed a slight increase in Mstn expression in vivo upon
AntagomiR injection, which we suggest may account for the
subtle atrophy phenotype observed. Nevertheless, we did note a
significant reduction in the numbers of Pax7+ cells and activated
myoblasts (MyoD+) upon AntagomiR-mediated blockade of miR-
27a in vivo, further confirming that miR-27 is able to regulate Mstn.
Taken together these data presented here strongly support that
miR-27a/b negatively regulates both Mstn expression and function
in vitro and in vivo. Importantly, in our current experiments we did
not observe any significant difference in the ability of miR-27a or
miR-27b to regulate Mstn expression or activity. Given that miR-
27a and miR-27b have the same ‘‘seed’’ sequence, UGACACU,
which recognizes complementary sequences in the 39UTRs of
target genes, it is not surprising that we found no difference in the
ability of miR-27a or miR-27b to regulate Mstn.
To date several studies have shown that Mstn expression is
relatively higher in fast twitch muscle fibers, when compared to
slow twitch muscle fibers [13,14]. Recently published evidence
suggests that miR-27 may play a role in regulating skeletal muscle
fiber type-specific expression of Mstn [23]. Specifically, work from
Allen and Loh revealed that miR-27a and miR-27b fast-twitch
and slow-twitch muscle-specific expression was complementary to
that of Mstn. In the current manuscript we also found a similar
trend in miR-27a/b and Mstn expression between fast and slow
muscle fiber types. Interestingly, here we further show that miR-
27a/b and Mstn expression was inversely associated between
different tissues. Specifically, when compared to heart tissue, we
noted higher Mstn expression, concomitant with reduced expres-
sion of miR-27a/b in liver tissue. It is noteworthy to mention that
although expression of Mstn has been detected in Liver previously
[41,42], high expression of Mstn in the Liver, as shown here, has
not been previously reported. We speculate that variations in the
expression of Mstn detected in Liver tissue between various studies
may be due to differences in the sensitivity of the techniques used
to assess for Mstn expression. In addition to regulating fiber type-
and tissue-specific Mstn expression, we also show that miR-27a/b
could potentially regulate Mstn mRNA levels during myogenic
differentiation in vitro. As differentiation ensued we noted a
decrease in Mstn expression, consistent with previous reports
[43,44], concomitant with a steady increase in miR-27 expression.
These data are in agreement with a recently published report by
Chen et al, which shows a similar increase in miR-27 expression
and associated decrease in Mstn expression during myogenic
differentiation [45]. As Mstn is a potent negative regulator of
myoblast differentiation [6], we speculate that the elevated miR-27
expression may function to inhibit Mstn expression thus allowing
for myogenic differentiation to proceed. Although it is tempting to
suggest that epigenetic mechanisms (such as miR-27) could be
responsible for regulating Mstn expression during differentiation,
we noted that the increase in miR-27 expression during
differentiation might not be enough to account for the dramatic
drop in Mstn expression observed. These data suggest that
additional factors may play a role in inhibiting Mstn during
differentiation. One likely candidate, that may be responsible for
regulating Mstn expression during differentiation, is Smad7.
Consistent with this, previously published work from our lab
clearly demonstrates that Smad7 is able to inhibit Mstn expression
[16]. Moreover, Kollias et al have previously demonstrated that the
expression of Smad7 is elevated during differentiation and that
over expression of Smad7 results in enhanced myogenic differen-
tiation and rescue of Mstn-mediated inhibition of differentiation
[46]. However, further work will need to be performed to confirm
this. A role for miR-27 in regulating myogenic differentiation is
not novel, in fact Crist et al recently demonstrated that miR-27b is
able to negatively regulate Pax3 protein levels in adult muscle
satellite cells to allow for timely entry into the myogenic
differentiation program [40]. Therefore, taken together these data
suggest that posttranscriptional regulation of Mstn mRNA by miR-
27 plays a critical role in controlling timely tissue-specific
expression/activity of Mstn during development.
Recently, we have shown that Smad3-null mice have elevated
expression of Mstn and not surprisingly pronounced skeletal
muscle atrophy [35]. Here we have investigated if miR-27a/b
could be responsible for the increased Mstn expression observed in
Smad3-null mice; and in agreement with increased Mstn expression
we find reduced miR-27a and miR-27b expression in Smad3-null
mice. More importantly, mimic-mediated over expression of miR-
27b in Smad3-null mice was able to reduce Mstn expression back to
levels comparable to WT mice. Therefore we speculate that loss of
Smad3 leads to reduced miR-27a/b expression, which in turn
increases Mstn mRNA stability and or translation leading to
enhanced skeletal muscle wasting. These data, together with the
fact that specific inhibitor of Smad3 (SIS3) treatment was able to
significantly reduce miR-27a/b expression, suggest that Smad3
plays an important role in regulating endogenous miR-27a/b
expression. Further support for Smad3 regulation of miR-27 is
seen in published work from Sun et al, which revealed the presence
of a Smad binding element in the miR-24-2/miR-23a/miR-27a
Figure 6. Mstn treatment up regulates miR-27a/b expression via Smad3 to negatively auto-regulate it’s own expression. qPCR
analysis of pre-miR-27a/b expression in C2C12 myoblasts (A) and 48 h differentiated C2C12 myotubes (B) following 12 h treatment with conditioned
medium from either control CHO cells (CCM) or from CHO-cells designed to produce and secrete Mstn protein (CMM). Bars represent fold change
(relative to respective CCM control) 6 S.E.M (n = 3) normalized to U6 expression. p,0.05 (*) and p,0.01 (**). (C) Assessment of miR-27a and miR-27b
promoter-reporter luciferase activity in C2C12 myoblasts transfected with the miR-27a promoter (miR-27a pro), miR-27b promoter (miR-27b pro) or a
mutant miR-27b promoter reporter construct, where the smad binding site has been mutated (miR-27b pro-mut). Transfected C2C12 myoblasts were
treated without (CCM) or with CMM in the absence (0.05% DMSO) or presence of SIS3 (10 mM) for 24 h prior to assessment of luciferase activity. All
luciferase activity was normalized to Renilla luciferase and expressed as fold change relative to respective controls (CCM+DMSO). Bars represent mean
values 6 S.E.M (n = 3). p,0.05 (*), p,0.01 (**) and p,0.001 (***). (D) Assessment of pMIR-REPORTTM luciferase activity in C2C12 myoblasts co-
transfected withMstn 39UTR and either AntagomiR Neg, AntagomiR-27a or AntagomiR-27b in the absence (2) or presence (+) of CMM. Bars represent
mean values 6 S.E.M (n = 3). p,0.001 (***). (E) Assessment of pMIR-REPORTTM luciferase activity in C2C12 myoblasts co-transfected with Mstn 39UTR-
mut and either AntagomiR Neg, AntagomiR-27a or AntagomiR-27b in the absence (2) or presence (+) of Mstn protein (CMM). Bars represent mean
values 6 S.E.M (n = 3). All luciferase activity was normalized to Renilla luciferase and expressed as fold change relative to control (CMM - and
AntagomiR Neg +). (F) Based on the data presented in this current manuscript we propose that upon Mstn-mediated receptor activation Smad3 up-
regulates the expression of miR-27a/b, which in turn leads to reduced Mstn expression and impaired Mstn function, thus forming the basis of a novel
negative Mstn auto-regulatory loop in muscle.
doi:10.1371/journal.pone.0087687.g006
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cluster upstream regulatory sequence and that the Smad binding
site was critical for TGF-b1-mediated inhibition of miR-24-2/
miR-23a/miR-27a [31].
Interestingly, we now show for the first time that Mstn is able to
up regulate the expression of miR-27a/b. Furthermore, Smad3 is
critical for Mstn regulation of miR-27a/b as either mutation of the
Smad binding site or treatment with SIS3 ablated the Mstn-
mediated response. Mstn has been previously shown to negatively
feedback to block its own expression/activity, through mecha-
nisms involving inhibition of Mstn proteolytic processing and
Smad7-dependent inhibition of Mstn expression [12,16]. Here we
now describe an independent mechanism through which Mstn
regulates it’s own expression. Specifically, addition of exogenous
Mstn resulted in increased miR-27a/b expression, which in turn
led to reduced Mstn 39 UTR activity. This mechanism was
dependent on miR-27a/b, as either blockade of miR-27a/b or
mutation of the miR-27a/b binding site in the Mstn 39 UTR
prevented Mstn feedback regulation. These data, together with
previously published work, suggest that there are independent
auto-regulatory mechanisms through which Mstn regulates it’s
own activity; given the fact that Mstn is a potent negative regulator
of skeletal muscle myogeneis, we speculate that such mechanisms
are in place to allow for timely regulation of myogenesis.
In summary, we provide further evidence to support a role for
miR-27 in regulating Mstn expression. Evidence suggests that
miR-27a and miR-27b play an important role in controlling tissue-
specific and muscle fiber type-specific expression of Mstn and
regulating Mstn function during myogenesis. Furthermore, we
now show that miR-27a/b forms the basis of a novel negative
auto-regulatory mechanism through which Mstn inhibits it’s own
expression in muscle.
Supporting Information
Figure S1 AntagomiR-mediated inhibition of miR-27a/
b and enhanced expression of Mstn. (A) qPCR analysis of
miR-27a expression in C2C12 myoblasts following transfection of
AntagomiR Neg or AntagomiR-27a. Bars represent fold change
(relative to AntagomiR Neg control) 6 S.E.M (n= 3) normalized
to U6 expression. p,0.001 (***). (B) qPCR analysis of miR-27b
expression in C2C12 myoblasts following transfection of Antag-
omiR Neg or AntagomiR-27b. Bars represent fold change (relative
to AntagomiR Neg control) 6 S.E.M (n= 3) normalized to U6
expression. p,0.001 (***). (C) qPCR analysis of Mstn expression in
C2C12 myoblasts following transfection of AntagomiR Neg,
AntagomiR-27a or AntagomiR-27b. Bars represent fold change
(relative to AntagomiR Neg control) 6 S.E.M (n= 3) normalized
to GAPDH expression. p,0.05 (*) and p,0.01 (**). (D) qPCR
analysis of Mstn expression in differentiated C2C12 myotubes
following transfection of AntagomiR Neg, AntagomiR-27a or
AntagomiR-27b. Bars represent fold change (relative to Antag-
omiR Neg control) 6 S.E.M (n= 3) normalized to GAPDH
expression. p,0.001 (***). (E) qPCR analysis of miR-27a
expression in differentiated primary myoblast cultures from
Mstn-null mice following transfection of AntagomiR Neg or
AntagomiR-27a. Bars represent fold change (relative to Antag-
omiR Neg control) 6 S.E.M (n= 3) normalized to U6 expression.
p,0.001 (***). qPCR analysis of miR-27a (F) and Mstn (G)
expression in differentiated primary myoblast cultures from WT
mice following transfection of AntagomiR Neg or AntagomiR-
27a. Bars represent fold change (relative to AntagomiR Neg
control) 6 S.E.M (n= 3) normalized to U6 (F) or GAPDH (G)
expression. p,0.001 (***). (H) Upper panel: Representative
immunofluorescence images showing Pax7+ cells (Green; white
arrowheads) in an in vivo transfected TA muscle cross section from
WT mice. Nuclei were counterstained with DAPI (Blue) and a
Pax7/DAPI merged image is also shown. Scale bars = 10 mm.
Lower panel: Representative immunofluorescence images showing
MyoD+ cells (Red; white arrowheads) in an in vivo transfected TA
muscle cross section from WT mice. Nuclei were counterstained
with DAPI (Blue) and a MyoD/DAPI merged image is also shown.
Scale bars = 100 mm.
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